Avacta Group appoints Shaun Chilton as non-executive chairman
LONDON: Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, announced that Shaun Chilton has been appointed...
Avacta Group acquires Coris Bioconcept to expand diagnostics business
LONDON, UK: Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announced today that it has acquired...
AffiDX lateral flow test detects Delta Variant
LONDON, UK: Avacta Group plc announced that a study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2...
Avacta Group enters into distribution agreement with ABCAM
LONDON: Avacta Group has entered into a global distribution agreement with ABCAM plcto sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer reagents. Avacta has...
Avacta Group signs commercial partnership with Mologic
LONDON: Avacta Group has entered into a commercial partnership with Mologic Ltd to accelerate to market Avacta’s AffiDX SARS-CoV-2 lateral flow rapid antigen test. Avacta...
Avacta signs collaboration agreement with Bruker
LONDON: Avacta Group plc has entered into a collaboration agreement with Bruker Corporation to evaluate the Affimer-based, bead assisted mass spectrometry (BAMSTM) SARS-CoV-2 assay, that...
Avacta and Daewoong collaborate to develop next generation cell and gene therapies
LONDON: Avacta Group plc has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, and...
Avacta signs collaboration and option agreement with ADC Therapeutics
LONDON: Avacta Group plc, a biotechnology company developing novel cancer immunotherapies based on its proprietary Affimer platform, has entered a collaboration and option agreement with...